Illumina (NASDAQ:ILMN) Insider Sells $110,700.00 in Stock

Illumina, Inc. (NASDAQ:ILMN) insider Scott Davies sold 615 shares of the company’s stock in a transaction on Thursday, June 25th. The shares were sold at an average price of $180.00, for a total value of $110,700.00. Following the completion of the transaction, the insider directly owned 20,953 shares in the company, valued at $3,771,540. This trade represents a 2.85% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Illumina Stock Down 0.6%

NASDAQ:ILMN opened at $176.55 on Friday. Illumina, Inc. has a twelve month low of $88.00 and a twelve month high of $182.84. The company has a market cap of $26.71 billion, a price-to-earnings ratio of 32.10, a price-to-earnings-growth ratio of 3.30 and a beta of 1.50. The stock has a fifty day simple moving average of $149.62 and a 200-day simple moving average of $137.66. The company has a current ratio of 1.75, a quick ratio of 1.36 and a debt-to-equity ratio of 0.56.

Illumina (NASDAQ:ILMN) last posted its quarterly earnings results on Thursday, April 30th. The life sciences company reported $1.15 EPS for the quarter, topping analysts’ consensus estimates of $1.05 by $0.10. The firm had revenue of $1.09 billion for the quarter, compared to analysts’ expectations of $1.07 billion. Illumina had a net margin of 19.42% and a return on equity of 31.01%. The business’s revenue for the quarter was up 4.8% on a year-over-year basis. During the same period in the prior year, the business posted $0.97 earnings per share. Illumina has set its FY 2026 guidance at 5.150-5.300 EPS. Analysts anticipate that Illumina, Inc. will post 5.21 EPS for the current year.

Analyst Ratings Changes

Several research analysts recently issued reports on the company. JPMorgan Chase & Co. raised Illumina from a “neutral” rating to an “overweight” rating and increased their price objective for the stock from $125.00 to $185.00 in a research note on Wednesday, June 10th. Barclays raised their price target on Illumina from $122.00 to $145.00 and gave the company an “underweight” rating in a research note on Wednesday. Daiwa Securities Group upgraded shares of Illumina from a “neutral” rating to an “outperform” rating and set a $155.00 target price on the stock in a report on Thursday, May 14th. Royal Bank Of Canada initiated coverage on shares of Illumina in a report on Thursday, May 14th. They issued an “outperform” rating and a $170.00 price target for the company. Finally, Citigroup increased their price objective on shares of Illumina from $80.00 to $95.00 and gave the company a “sell” rating in a research note on Monday, May 4th. Eight research analysts have rated the stock with a Buy rating, nine have given a Hold rating and two have assigned a Sell rating to the stock. According to data from MarketBeat, the stock has a consensus rating of “Hold” and a consensus price target of $146.00.

Hedge Funds Weigh In On Illumina

Large investors have recently added to or reduced their stakes in the company. Elyxium Wealth LLC purchased a new position in shares of Illumina in the 4th quarter worth approximately $25,000. Board of the Pension Protection Fund acquired a new stake in Illumina in the fourth quarter valued at approximately $26,000. Creative Capital Management Investments LLC boosted its stake in Illumina by 160.0% in the fourth quarter. Creative Capital Management Investments LLC now owns 195 shares of the life sciences company’s stock valued at $26,000 after acquiring an additional 120 shares in the last quarter. TD Waterhouse Canada Inc. purchased a new position in Illumina in the fourth quarter worth $26,000. Finally, Laurel Wealth Advisors LLC purchased a new position in Illumina in the fourth quarter worth $26,000. 89.42% of the stock is currently owned by institutional investors.

About Illumina

Illumina, Inc (NASDAQ: ILMN) is a global life sciences company that develops, manufactures and markets integrated systems for the analysis of genetic variation and function. Headquartered in San Diego, California and founded in 1998, Illumina offers a range of sequencing and array-based technologies used by academic researchers, clinical laboratories, pharmaceutical and biotechnology companies, consumer genomics firms and agricultural researchers to enable discovery, translational research and clinical applications.

The company’s product portfolio includes next-generation sequencing (NGS) platforms and associated consumables, microarrays for genotyping and methylation analysis, library preparation kits and targeted assays.